PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Although classified under KOSPI's bio/pharma sector, InBioGen's actual business is kiosk distribution and F&B, with its stake in Vidente—linked to Bithumb's governance chain—serving as the key variable in the company's value.
The core business is unmanned kiosk distribution and F&B, which differs from its nominal bio/pharma sector classification.
The company posted operating losses for four consecutive years from 2022 to 2025, with revenue shrinking to the several-billion-won range.
Net income shows large volatility unrelated to core quarterly revenue, with net losses recorded for three consecutive recent quarters.
InBioGen holds a stake in Vidente, which is the single largest shareholder of Bithumb Holdings and a core link in Bithumb's governance structure.
Vidente was granted another five-month improvement period by the KOSDAQ Market Committee in July 2026, set to expire on December 22, 2026.
InBioGen is listed on the KOSPI and classified under the bio/pharma sector, but according to disclosures and corporate information, the company—founded in 2008—actually operates in kiosk distribution and F&B business.
The kiosk business has expanded from banks and subway stations into restaurants, public institutions, hospitals, and unmanned stores, driven by labor cost pressures from inflation and minimum wage increases as well as growing demand for contactless service.
The company describes the global kiosk market as growing at an average annual rate of 12.3%, reaching roughly $51.05 billion by 2028. Enjoysoft is cited among the major clients for the kiosk business.
The F&B segment targets the MZ generation with menu development and service differentiation, aiming to build competitiveness through food-tech-based innovation.
However, this core business generates only several billion won in annual revenue, far smaller than the company's shareholders' equity of 157.6 billion won at the end of 2025.
This mismatch between assets and revenue is tied to InBioGen's roughly 47% stake in affiliate Vidente, which is in turn the single largest shareholder (34.22% stake) of Bithumb Holdings, the parent of cryptocurrency exchange Bithumb.
The governance chain runs from Initial No.1 Investment Association, where CEO Kang Ji-yeon is the largest shareholder, through Bucket Studio, InBioGen, and Vidente to Bithumb Holdings, with Vidente also holding a portion of Bucket Studio shares in a circular ownership structure.
Understanding InBioGen's corporate value therefore requires looking beyond the surface-level kiosk and F&B business to the value of its Vidente equity stake.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩1.8B | -₩1B | −54.3% |
| 2025Q3 | ₩2.1B | -₩1.1B | −49.1% |
| 2025Q4 | ₩700M | -₩1B | −144.3% |
| 2026Q1 | ₩800M | -₩1B | −124.6% |
| 2026Q2 | ₩1.5B | -₩900M | −61.2% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩11.4B | -₩6.3B | -₩117.2B | −55.5% | −109.7% | 35.0% |
| 2023 | ₩6.2B | -₩6.2B | ₩11.3B | −98.6% | 7.9% | 1.8% |
| 2024 | ₩7B | -₩6.1B | ₩16.1B | −86.5% | 10.1% | 1.8% |
| 2025 | ₩6.3B | -₩4.3B | -₩1.4B | −68.8% | −0.9% | 1.5% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Based on the confirmed financials, InBioGen recorded operating losses in all four years from 2022 through 2025.
Revenue contracted and stagnated, moving from 11.4 billion won in 2022 to 6.2 billion won in 2023, 7.0 billion won in 2024, and 6.3 billion won in 2025, while the operating margin remained deeply negative at -68.8% in 2025, -86.5% in 2024, and -98.6% in 2023.
Net income, however, fluctuated sharply and largely independently of operating results: attributable net income swung from a massive loss of -117.2 billion won in 2022 to profits of 11.3 billion won in 2023 and 16.1 billion won in 2024, before reverting to a loss of -1.4 billion won in 2025.
This volatility is equally visible on a quarterly basis.
Attributable net income was a profit of about 8.2 billion won in the third quarter of 2025, but swung to losses of -12.7 billion won in the fourth quarter of 2025 and -14.7 billion won in the first quarter of 2026, before narrowing to a loss of about -1.5 billion won in the second quarter of 2026.
Revenue over the same period ranged widely, from 1.8 billion won in the second quarter of 2025 down to 0.7 billion won in the fourth quarter of 2025, before rising back to 1.5 billion won in the second quarter of 2026.
The cumulative attributable net loss over the trailing four quarters (Q3 2025–Q2 2026) totaled -20.7 billion won, in contrast to comparatively stable quarterly operating losses ranging from -9.2 billion won to -10.5 billion won.
This pattern suggests net income swings are driven more by investment asset valuation or non-operating factors than by core kiosk and F&B activity, and operating cash flow also remained negative at -5.6 billion won in 2025, continuing a multi-year negative trend.
Although classified under bio/pharma on the KOSPI, InBioGen's actual industry exposure is unmanned payment kiosks and F&B distribution, underpinned by structural demand from rising domestic labor costs and expanding contactless services.
The company describes the global kiosk market as growing at an average annual rate of 12.3% to reach roughly $51.05 billion by 2028, though this is a fragmented market with numerous hardware and software vendors competing, not one dominated by a single player.
The industry axis that actually draws investor attention, however, is the cryptocurrency exchange sector.
InBioGen's stake in Vidente, the single largest shareholder (34.22% stake) of Bithumb Holdings, which operates one of Korea's top cryptocurrency exchanges, makes it a central party in ongoing discussions about the governance restructuring of domestic crypto exchanges.
Vidente and its sister company Bucket Studio have repeatedly been subject to listing-eligibility reviews following investigations into embezzlement and breach-of-trust allegations against a figure previously identified as the real owner, Kang Jong-hyun, and market observers note that resolving this governance risk could affect Bithumb's IPO progress and the valuation of related affiliates.
In short, while InBioGen is nominally classified in bio/pharma, its actual industry cycle and valuation dynamics are more closely tied to the governance restructuring phase of Korea's crypto exchange industry than to the kiosk and F&B market.
Given that the core kiosk and F&B business remains small in scale and has posted operating losses for four consecutive years, there is no confirmed basis to expect a near-term turnaround from core operations alone.
The variable more likely to affect overall corporate value is the governance resolution process surrounding Vidente.
Vidente was granted another five-month improvement period by the KOSDAQ Market Committee on July 22, 2026, with the period set to end on December 22, 2026, after which the company must submit an implementation report within 15 business days.
Vidente and Bucket Studio are reportedly preparing a second public sale process with Samjong KPMG as advisor, after an earlier sale to prospective buyer Wabisabi Holdings fell through due to non-payment of the interim and final installments.
If this sale is completed and effectively severs the influence of the Kang family, Vidente's chances of maintaining its listing would improve, which could also affect how the value of InBioGen's Vidente stake is assessed.
Conversely, if the sale again fails or the improvement plan is judged insufficient, delisting proceedings for Vidente could resume, which would be a negative variable for the value of InBioGen's investment assets.
The progress of these governance events is likely to be the key variable reflected in the valuation of InBioGen's investment assets going forward.
InBioGen's shares trade at a level discounted relative to the company's net asset value. However, a substantial portion of that net asset base consists of investment holdings such as the Vidente stake, meaning conventional operating-performance-based valuation yardsticks may not fully apply.
Net income has also swung between losses and profits over recent years without a consistent direction, and with net losses recorded in three consecutive recent quarters, profit-based valuation metrics are difficult to apply reliably in the current period.
On dividends, the company has not paid cash dividends through the most recent fiscal year.
Ultimately, assessing this stock requires weighing both the potential recovery of profitability in the core kiosk and F&B business and the eventual outcome of the governance resolution process affecting the value of its Vidente equity stake.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Demand for labor-cost savings amid inflation and rising minimum wages, along with the spread of contactless services, is expanding kiosk use beyond banks and subways into restaurants, public institutions, and hospitals.
The company describes itself as operating in a market projected to grow at an average annual rate of 12.3% to reach roughly $51.05 billion by 2028. This structural demand can be seen as potential room for growth in core business revenue.
InBioGen holds a stake in Vidente, which is the single largest shareholder (34.22% stake) of Bithumb Holdings, operator of Korea's Bithumb crypto exchange.
If the governance resolution and a second public sale involving Vidente succeed, its chances of maintaining its listing would improve, which could affect the valuation of InBioGen's investment assets. Ongoing discussions about Bithumb's IPO progress are also a related factor to watch.
The debt ratio stood at a very low 1.5% in 2025, down markedly from 35.0% in 2022. Shareholders' equity increased from 106.9 billion won in 2022 to 157.6 billion won in 2025. Even amid persistent operating losses, the financial structure itself, with low reliance on external borrowing, has remained stable.
The company recorded operating losses in all four years from 2022 to 2025, with the operating margin maintaining a large deficit of between -55% and -99% each year. Revenue also shrank from 11.4 billion won in 2022 to 6.3 billion won in 2025.
On a quarterly basis, operating losses have consistently occurred at roughly -0.9 billion to -1.1 billion won per quarter.
Attributable net income swung from a massive loss of -117.2 billion won in 2022 to profits in 2023–2024, before reverting to a loss of -1.4 billion won in 2025. Three of the last four quarters (Q4 2025, Q1 2026, Q2 2026) posted consecutive net losses, with a cumulative loss of -20.7 billion won over that period.
This volatility appears to stem from factors unrelated to core operations, reducing the predictability of results.
InBioGen's largest shareholder-linked figure, CEO Kang Ji-yeon, is the sister of Kang Jong-hyun, who has faced allegations of being the real owner of Bithumb, and legal risk associated with Kang Jong-hyun has repeatedly triggered listing-eligibility issues across affiliated companies.
Vidente and Bucket Studio have repeatedly been subject to listing-eligibility reviews, and an earlier public sale attempt fell through due to non-payment by the buyer. It has also been confirmed that a court froze Vidente's Bithumb Holdings shares in connection with allegations against Kang Jong-hyun.
At the top of InBioGen's governance chain is Initial No.1 Investment Association, where CEO Kang Ji-yeon is the largest shareholder, while her brother Kang Jong-hyun has been undergoing legal proceedings over allegations of being Bithumb's real owner.
As a result, Vidente and Bucket Studio have repeatedly been subject to listing-eligibility reviews, leaving the listing status of affiliated companies broadly uncertain. This risk could also negatively affect the valuation of InBioGen's investment assets.
InBioGen's net income appears to be more heavily influenced by fluctuations in the value of affiliate stakes such as Vidente than by core operating activity. With large net losses recorded in three of the last four quarters, earnings volatility from investment asset revaluation could persist going forward. This makes standard earnings forecasting through the financial statements more difficult.
The kiosk and F&B business generates only several billion won in annual revenue, a level insufficient to achieve economies of scale, and it is difficult to identify a clear competitive edge in a fragmented market with numerous rivals.
Given four consecutive years of operating losses, the possibility of delayed profitability recovery in the core business cannot be ruled out.
Once Q3 2026 results are disclosed, it will be important to check whether the recent quarterly net income volatility continues and whether core kiosk/F&B revenue shows signs of recovery.
This marks the end of Vidente's improvement period, after which the KOSDAQ Market Committee is expected to re-review whether to delist the company. The outcome could directly affect the valuation of InBioGen's Vidente equity stake.
It will be worth checking whether the second public sale of Bucket Studio and Vidente, being prepared with Samjong KPMG as advisor, resumes, and whether a completed sale effectively severs the Kang family's control.
Depending on whether Vidente's listing-eligibility risk is resolved, how discussions on Bithumb's IPO progress evolve is also a related factor to monitor.
InBioGen is classified under KOSPI's bio/pharma sector, but its actual core business is kiosk distribution and F&B, which posted operating losses for four consecutive years from 2022 to 2025 while revenue also contracted.
Net income moved independently of this trend, swinging from a massive loss in 2022 to profits in 2023–2024 and back to a loss in 2025, with net losses recorded in three of the last four quarters.
This earnings pattern suggests that the core of the company's value lies less in kiosk/F&B operations and more in its Bithumb-related investment assets held through its Vidente stake.
Vidente faces the end of its improvement period on December 22, 2026, and the outcome of the second public sale and governance resolution process during this period is expected to be a direct variable for the value of InBioGen's investment assets.
While the financial structure itself appears stable, with a low debt ratio, two uncertainties coexist: the recovery of core business profitability and the resolution of affiliate governance risk.
Investors will need to consider this dual structure—the surface-level kiosk/F&B business and the substantive value of its Bithumb-affiliate equity stake—while monitoring future disclosures and market developments.
Report written 2026-09-12 · Data as of 2026-09-11
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.